Aptose Biosciences (APTO) Stock Rating Reaffirmed by H.C. Wainwright; The $4.0 Target Indicates 104.08% Potential; Oppenheimer Holdings (OPY) Sentiment Is 0.72

November 15, 2017 - By Adrian Erickson

Oppenheimer Holdings Inc. is a middle-market investment bank and service broker-dealer. The company has market cap of $320.52 million. The Firm is engaged in a range of activities in the securities industry, including retail securities brokerage, institutional sales and trading, investment banking, research, market-making, trust services, and investment advisory and asset management services. It currently has negative earnings.

Among 4 analysts covering Aptose Biosciences (NASDAQ:APTO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Aptose Biosciences has $20 highest and $100 lowest target. $6.85’s average target is 249.49% above currents $1.96 stock price. Aptose Biosciences had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, November 11. The stock of Aptose Biosciences Inc (NASDAQ:APTO) earned “Hold” rating by H.C. Wainwright on Thursday, June 8. The rating was upgraded by Zacks on Friday, August 7 to “Hold”. The stock of Aptose Biosciences Inc (NASDAQ:APTO) has “Neutral” rating given on Friday, November 20 by Roth Capital. The stock has “Neutral” rating by TH Capital on Friday, November 20. RBC Capital Markets maintained the shares of APTO in report on Wednesday, November 16 with “Outperform” rating. The rating was upgraded by H.C. Wainwright to “Buy” on Thursday, September 7. Roth Capital upgraded the shares of APTO in report on Monday, June 13 to “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Monday, October 30 report. The firm earned “Hold” rating on Wednesday, August 9 by H.C. Wainwright.




Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company has market cap of $49.89 million. The Firm is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. It currently has negative earnings. The Company’s product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

It closed at $1.96 lastly. It is down 60.81% since November 15, 2016 and is downtrending. It has underperformed by 77.51% the S&P500.

It closed at $24.45 lastly. It is down 11.51% since November 15, 2016 and is uptrending. It has underperformed by 5.19% the S&P500.

Private Capital Management Llc holds 0.99% of its portfolio in Oppenheimer Holdings Inc. (USA) for 374,390 shares. Greenwich Wealth Management Llc owns 305,703 shares or 0.84% of their US portfolio. Moreover, Perritt Capital Management Inc has 0.6% invested in the company for 141,121 shares. The Virginia-based Outfitter Advisors Ltd. has invested 0.49% in the stock. Cove Street Capital Llc, a California-based fund reported 78,100 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.